Core Viewpoint - Rosen Law Firm is reminding investors who purchased Unicycive Therapeutics, Inc. securities during the specified class period of the upcoming lead plaintiff deadline on October 14, 2025 [1]. Group 1: Class Action Details - Investors who bought Unicycive securities between March 29, 2024, and June 27, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lead plaintiff must file a motion with the Court by October 14, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering substantial amounts for clients [4]. Group 3: Case Allegations - The lawsuit alleges that Unicycive's management made false or misleading statements regarding the company's compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application for oxylanthanum carbunate [5]. - It is claimed that these misrepresentations led to investor damages when the true information became public [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Tronox Holdings plc due to misleading statements and a significant decline in financial performance, urging affected investors to take action before the November 3, 2025 deadline for lead plaintiff applications [4][6]. Company Performance - Tronox reported a significant reduction in TiO2 sales for Q2 2025, attributing the decline to a softer coatings season and increased competition, leading to a lowered full-year revenue guidance and a 60% reduction in dividends [7]. - Following the announcement of poor financial results, Tronox's stock price plummeted from $5.14 to $3.19 per share, marking a decline of approximately 38% in just one day [8]. Legal Context - A federal securities class action has been filed against Tronox, with a deadline of November 3, 2025, for investors to seek the role of lead plaintiff [4][9]. - The lead plaintiff is defined as the investor with the largest financial interest who can adequately represent the class [9]. Investor Communication - Faruqi & Faruqi encourages anyone with information regarding Tronox's conduct, including whistleblowers and former employees, to come forward [10].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Nutex Health Inc. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Nutex securities between August 8, 2024, and August 14, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by October 21, 2025 [3][6]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against Nutex - The lawsuit alleges that Nutex made false and misleading statements regarding its financial practices and internal controls, particularly concerning its relationship with HaloMD, a third-party vendor [5]. - Specific claims include that Nutex engaged in a scheme to defraud insurance companies, leading to unsustainable revenue and improper accounting of stock-based compensation obligations [5]. - The lawsuit asserts that these misrepresentations resulted in overstated business and financial prospects for Nutex, causing investor damages when the truth was revealed [5].